Suppr超能文献

早期同时引入心力衰竭治疗四支柱策略:单中心经验结果。

Strategy for an early simultaneous introduction of four-pillars of heart failure therapy: results from a single center experience.

机构信息

Department of Clinical, Internal, Anesthesiology and Cardiovascular Sciences, Sapienza University of Rome, Viale del Policlinico 155, 00161, Rome, Italy.

出版信息

Am J Cardiovasc Drugs. 2024 Sep;24(5):663-671. doi: 10.1007/s40256-024-00660-6. Epub 2024 Jun 23.

Abstract

INTRODUCTION

The 2021 European Society of Cardiology (ESC) Guidelines recommend the use of four different classes of drugs for heart failure with reduced ejection fraction (HFrEF): beta blockers (BB), sodium-glucose cotransporter-2 inhibitors (SGLT2i), angiotensin receptor/neprilysin inhibitor (ARNI), and mineralocorticoid receptor antagonists (MRAs). Moreover, the 2023 ESC updated Guidelines suggest an intensive strategy of initiation and rapid up-titration of evidence-based treatment before discharge, based on trials not using the four-pillars. We hypothesized that an early concomitantly administration and up-titration of four-pillars, compared with a conventional stepwise approach, may impact the vulnerable phase after hospitalization owing to HF.

METHODS

This prospective, single center, observational study included consecutive in-hospital patients with HFrEF. After performing propensity score matching, they were divided according to treatment strategy into group 1 (G1), with predischarge start of all four-pillars, with their up-titration within 1 month, and group 2 (G2) with the pre Guidelines update stepwise four-pillars introduction. HF hospitalization, cardiovascular (CV) death, and the composite of both were evaluated between the two groups at 6-month follow-up.

RESULTS

The study included a total of 278 patients who completed 6-month follow-up (139 for both groups). There were no differences in terms of baseline features between the two groups. At survival analysis, HF hospitalization risk was significantly lower in G1 compared with G2 (p < 0.001), while no significant differences were observed regarding CV death (p = 0.642) or the composite of CV death and HF hospitalization (p = 0.135).

CONCLUSIONS

In our real-world population, patients with HF treated with a predischarge and simultaneous use of four-pillars showed a reduced risk of HF hospitalization during the vulnerable phase after discharge, compared with  a conventional stepwise approach.

摘要

简介

2021 年欧洲心脏病学会(ESC)指南建议使用四类药物治疗射血分数降低的心力衰竭(HFrEF):β受体阻滞剂(BB)、钠-葡萄糖共转运蛋白 2 抑制剂(SGLT2i)、血管紧张素受体/脑啡肽酶抑制剂(ARNI)和盐皮质激素受体拮抗剂(MRA)。此外,2023 年 ESC 更新指南建议在出院前根据未使用四药治疗的试验,采用强化策略启动和快速滴定基于证据的治疗。我们假设与传统的逐步方法相比,早期同时给予和滴定四药可能会影响因 HF 导致的住院后脆弱期。

方法

这是一项前瞻性、单中心、观察性研究,纳入了连续住院的 HFrEF 患者。在进行倾向评分匹配后,根据治疗策略将患者分为两组:组 1(G1),在出院前开始使用所有四药,并在 1 个月内进行滴定;组 2(G2),采用指南更新前的逐步四药引入策略。在 6 个月的随访中,评估两组之间的 HF 住院、心血管(CV)死亡和两者的复合终点。

结果

该研究共纳入 278 例完成 6 个月随访的患者(每组 139 例)。两组患者的基线特征无差异。生存分析显示,G1 组 HF 住院风险明显低于 G2 组(p < 0.001),而 CV 死亡(p = 0.642)或 CV 死亡和 HF 住院的复合终点(p = 0.135)无显著差异。

结论

在我们的真实世界人群中,与传统的逐步方法相比,在出院后脆弱期,使用预出院和同时使用四药治疗的 HF 患者 HF 住院风险降低。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c204/11344711/f18a76baaa6f/40256_2024_660_Fig1_HTML.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验